Take a remedial reading course,re-read my post below and report back.
FLML,on its current story,should be substantially higher.I'm questioning why Deerfield
and friends tolerate the weak,flaccid and bumbling IR "effort" of CEO Anderson.
You better hope for some positive news because in a possible market correction,
continued selling by JP Morgan,Jennison, Millenium Consonance and Fido will put a
dent in your 300% gain in FLML
All of these unbalanced Obama lovers are mentally disturbed
Why is Deerfield letting its FLML investment underperform its moon shot potential?
FLML's Investor Relation's "effort" is flaccid,bumbling and totally bereft of stock market savvy.CEO
Anderson is depressingly-" inept in boosting shareholder values.On its fundamental story,a competent
IR effort communicating where FLML is going would have the stock above $30 today.
Deerfield and friends own a controlling interest in FLML but it continues amateur hour in
the pathetic lack of skill in promoting the stock.This stock has only 35 MM shares not a billion.
It should be a moon shot but investors continue to suffer "gentle price decreases" that further
demoralizes shareholders and significantly boosts the discount rate on what should be a winning story.
The "door will be very narrow"if the long overdue stock market correction actually occurs.Selling by
demoralized Flamel shareholders,the hot money hedgies and disenchanted friends of Deerfield
could cause a collapse in FLML's volatile stock unless the amateur hour managers in Lyon
do a much more effective communication of The Case For Flamel in conjunction with
some major improvements in the fundamentals( that could offset a weak stock market).Right now
FLML stock should be substantially higher but this requires a now-missing, competent investor relations
effort by CEO Anderson.
a few more days of "gentle price decreases" and your wife will
need a second mortgage to support her spending.
Deerfield needs to install a strong IR effort replacing CEO Anderson's
bumbling,flaccid, amateur hour "effort"
The company-making implications of the PR and its several impacts on
the fundamentals are huge.but you wouldn't know it from the company's
flaccid,uninformative communication this morning.
Svchiro is right on FLML's fundamentals but this stock should be in the
When is Deerfield going to wake up?
when we raise the victory flag.I do believe that Anderson et al are working hard on
the fundamentals but a flaccid,bumbling IR effort is retarding the stock.Deerfield should recognize this
critical problem and fix it.
With an effective IR effort and less amateur hour moments with Anderson,FLML should already exceed
Wall Street's $21-25 Price Objectives.
Deerfield is leaving lots of money on the table
This Bartender will rejoice if we can meet in Paris for a victory party,at the Flamel Restaurant in The Marais
When are your Deerfield pals going to eliminate the current amateur hour performance of
CEO Anderson and the bumbling,incompetent IR "effort"????
Deerfield in its self interest should be doing a lot more to promote its investment in FLML.
Why are they content to be leaving lots of money on the table?
Deerfield may be great on fundamentals but they are amateurs managing FLML's stock.
Deerfield is leaving lots of money on the table ignoring the longer term damage caused by
the ever-increasing discount rate on its fundamental story
Ii it does,it is indeed a stealth effort.
Why does Deerfield tolerate an incompetent,flaccid effort by the control freak" CEO.
Summer Street and cvchiro may talk positively but they are getting no help
from the bumblers at FLML.
We continue to believe FLML's evolving fundamental story has homerun potential
but Deerfield and friends are leaving lots of money on the table.
everything is going great except the FLML stock price.
When is Deerfield going to install a high-powered IR program to start
reducing the very-high discount rate on the fundamental story
FLML's stealth IR program has discussed Éclat I and II,both now FDA approved.
Éclat III and IV have been delayed but both are supposed to be submitted for FDA
review in H2.
FLM is working on Éclat v and VI and has identified 20-30 additional candidates(that
have passed its screen).
The first 4 Éclat drugs are expected to have aggregate peak sales of about $1 Billion
with high gross margins and large TLC's bolstering net income.
So,the question is why are investors oblivious to FLML's stock market potential.Some would say
the sales estimates are too optimistic.Others would say that FLML's weak IR effort and a history of disappointment has caused a very-high discount rate on the fundamental story/earnings.This
Bartender is dismayed that Deerfield is tolerating amateur hour in Lyon because it is costing
Mr Flynn big money as FLML stock far underperforms its potential
regarding the large,peak sales potential of Eclat III,IV,V and VI.They do not know why Deerfield
tolerates "amateur hour" in top management,including an incompetent IR "effort" which is leaving lots of money on the table
for their Lyon-P Town flings with appreciated FLML stock.
These pub-goers complain about FLML top management,after several cocktails, and
appropriate back door activities.They lament the obivious, amateur hour fumbles
and the very-poor IR "effort" which is retarding FLML stock relative to the high
potential fundamentals previewed In earlier,and prescient, Svchiro posts herein.
Fun speaks the truth;DD Ag is a huge loser as the gap with the dominant MON grows larger
But Deerfield and CEO Anderson assure these pillaged investors
that "everything is going great `cept the stock price"
If FLML had even a mediocre IR program, compared to one of the
worst this Bartender has ever encountered,FLML stock could be
substantially higher on the same fundamental story.
Deerfield should terminate the amateur hour management in Lyon
and bring in a team that can execute
"her" husband and Arthur.That could be a classic windy that would attract
lots of new pub-goers to the Eastmoor Pub's world famous back door activities
Even flaccid IR programs would have been able to "plant"
a favorable Barron's story by now.
Isn't Deerfield concerned that FLML is underperforming its
stock market potential
Éclat III and IV to be submitted for FDA approval in H2 2014.Work continues on
Éclat V and VI
Yearly peak sales of these 6 drugs could be more than FLML's current market
FLML continues to make nice progress with its burgeoning fundamentals but the
the stock continues to underperform its potential being #$%$ by the financial
morons it employs to communicate its story to investors